Samsara Therapeutics

Samsara Therapeutics, a United Kingdom based startup founded in 2018, is dedicated to revolutionizing the treatment of age-related neurodegenerative diseases through the activation of autophagy. Their slogan "Treating Neurodegenerative Disease by Restoring Autophagy" encapsulates their mission to significantly impact the lives of patients and their families by delaying the progression of debilitating conditions. The company recently received a Series A investment on 06 September 2022 from notable investors FJ Labs and Healthspan Capital, signaling confidence in their innovative approach. Operating at the intersection of Biopharma, Biotechnology, and Pharmaceutical industries, Samsara Therapeutics is poised to drive significant advancements in the treatment of neurodegenerative diseases, making them a noteworthy player in the healthcare innovation landscape.